Global Precision Cancer Medicine Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Precision Cancer Medicine Market Research Report 2024
Precision cancer medicines, are medications designed to specifically target the unique genetic or molecular characteristics of an individual patient's cancer. These drugs are a central component of personalized cancer medicine and are chosen based on the genomic and molecular profiling of the patient's tumor.
According to Mr Accuracy reports’s new survey, global Precision Cancer Medicine market is projected to reach US$ 350430 million in 2029, increasing from US$ 161690 million in 2022, with the CAGR of 12.5% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Precision Cancer Medicine market research.
Precision cancer medicine, also known as personalized or targeted cancer therapy, is driven by the growing understanding of cancer's molecular and genetic complexity. Advances in genomics and biomarker identification have enabled the development of therapies tailored to an individual's specific cancer characteristics. This approach offers the potential for more effective treatments with fewer side effects compared to traditional chemotherapy. The market benefits from increasing research in oncology, the rise of precision diagnostics, and the growing availability of targeted therapies. However, challenges include the high cost of genetic testing and targeted treatments, as well as the need for comprehensive molecular profiling. Additionally, regulatory approvals and insurance coverage for these therapies can be complex. To maximize the potential of precision cancer medicine, stakeholders must address these challenges, improve accessibility, and continue research into novel biomarkers and therapies to provide tailored cancer care for patients.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Precision Cancer Medicine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
AbbVie
Johnson & Johnson
Novartis
Gilead Sciences
Roche
Bristol-Myers Squibb
Amgen
AstraZeneca
Merck & Co
Takeda
Merck KGaA
Seagen
Eli Lilly
Ono Pharmaceutical
Pfizer
GSK
Exelixis
Regeneron
Innovent
Hengrui Medicine
Segment by Type
Cancer Immunotherapy
Targeted Therapy
Lung Cancer
Breast Cancer
Prostate Cancer
Blood-related Cancer
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Precision Cancer Medicine report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Precision Cancer Medicine market is projected to reach US$ 350430 million in 2029, increasing from US$ 161690 million in 2022, with the CAGR of 12.5% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Precision Cancer Medicine market research.
Precision cancer medicine, also known as personalized or targeted cancer therapy, is driven by the growing understanding of cancer's molecular and genetic complexity. Advances in genomics and biomarker identification have enabled the development of therapies tailored to an individual's specific cancer characteristics. This approach offers the potential for more effective treatments with fewer side effects compared to traditional chemotherapy. The market benefits from increasing research in oncology, the rise of precision diagnostics, and the growing availability of targeted therapies. However, challenges include the high cost of genetic testing and targeted treatments, as well as the need for comprehensive molecular profiling. Additionally, regulatory approvals and insurance coverage for these therapies can be complex. To maximize the potential of precision cancer medicine, stakeholders must address these challenges, improve accessibility, and continue research into novel biomarkers and therapies to provide tailored cancer care for patients.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Precision Cancer Medicine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
AbbVie
Johnson & Johnson
Novartis
Gilead Sciences
Roche
Bristol-Myers Squibb
Amgen
AstraZeneca
Merck & Co
Takeda
Merck KGaA
Seagen
Eli Lilly
Ono Pharmaceutical
Pfizer
GSK
Exelixis
Regeneron
Innovent
Hengrui Medicine
Segment by Type
Cancer Immunotherapy
Targeted Therapy
Segment by Application
Lung Cancer
Breast Cancer
Prostate Cancer
Blood-related Cancer
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Precision Cancer Medicine report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices